These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 12181048)
61. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Khanna R; Burrows SR; Nicholls J; Poulsen LM Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052 [TBL] [Abstract][Full Text] [Related]
62. Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations. Chu PG; Chang KL; Chen WG; Chen YY; Shibata D; Hayashi K; Bacchi C; Bacchi M; Weiss LM Am J Pathol; 1999 Sep; 155(3):941-7. PubMed ID: 10487851 [TBL] [Abstract][Full Text] [Related]
63. [iPSC-derived rejuvenated T-cell therapy for Epstein-Barr virus-associated lymphomas]. Ando M; Nakauchi H; Komatsu N Rinsho Ketsueki; 2018; 59(7):932-938. PubMed ID: 30078805 [TBL] [Abstract][Full Text] [Related]
64. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Barker JN; Doubrovina E; Sauter C; Jaroscak JJ; Perales MA; Doubrovin M; Prockop SE; Koehne G; O'Reilly RJ Blood; 2010 Dec; 116(23):5045-9. PubMed ID: 20826724 [TBL] [Abstract][Full Text] [Related]
65. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. Savoldo B; Cubbage ML; Durett AG; Goss J; Huls MH; Liu Z; Teresita L; Gee AP; Ling PD; Brenner MK; Heslop HE; Rooney CM J Immunol; 2002 Jan; 168(2):909-18. PubMed ID: 11777989 [TBL] [Abstract][Full Text] [Related]
66. Regulatory T cells and EBV associated malignancies. Li J; Qian CN; Zeng YX Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572 [TBL] [Abstract][Full Text] [Related]
67. Immunotherapy for Hodgkin's disease. Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071 [TBL] [Abstract][Full Text] [Related]
68. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children. Chiou FK; Beath SV; Wilkie GM; Vickers MA; Morland B; Gupte GL Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29388302 [TBL] [Abstract][Full Text] [Related]
69. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma. Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179 [TBL] [Abstract][Full Text] [Related]
70. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors. Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947 [TBL] [Abstract][Full Text] [Related]
71. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Bollard CM; Cooper LJ; Heslop HE Best Pract Res Clin Haematol; 2008 Sep; 21(3):405-20. PubMed ID: 18790446 [TBL] [Abstract][Full Text] [Related]
73. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders. Swinnen LJ Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187 [TBL] [Abstract][Full Text] [Related]
74. Generation of cytotoxic T lymphocytes for immunotherapy of EBV-associated malignancies. Smith C; Khanna R Methods Mol Biol; 2010; 651():49-59. PubMed ID: 20686959 [TBL] [Abstract][Full Text] [Related]
75. Hepatitis C virus-Epstein-Barr virus interaction in patients with AIDS. Challine D; Buisson M; Cadilhac M; Germanidis G; Joab I; Eliaszewicz M; Caumes E; Flahault A; Fillet AM; Pawlotsky JM; Seigneurin JM J Med Virol; 2002 Aug; 67(4):510-5. PubMed ID: 12115996 [TBL] [Abstract][Full Text] [Related]
76. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290 [TBL] [Abstract][Full Text] [Related]
77. Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma. DiMaio JM; Van Trigt P; Gaynor JW; Davis RD; Coveney E; Clary BM; Lyerly HK Circulation; 1995 Nov; 92(9 Suppl):II202-5. PubMed ID: 7586409 [TBL] [Abstract][Full Text] [Related]
78. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304 [TBL] [Abstract][Full Text] [Related]
79. Immunotherapy against EBV-lymphoma in recipients of HSCT. Comoli P; Zecca M; Maccario R Expert Rev Hematol; 2010 Oct; 3(5):625-32. PubMed ID: 21083478 [TBL] [Abstract][Full Text] [Related]
80. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]